NCT00645177View on ClinicalTrials.gov

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Metastatic Breast Cancer
Interventions
DRUG

ABT-869

0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle

DRUG

paclitaxel

90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks

DRUG

Placebo for ABT-869

0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle

Trial Locations (3)

60426

Site Reference ID/Investigator# 6920, Harvey

94115

Site Reference ID/Investigator# 8352, San Francisco

CP 34000

Site Reference ID/Investigator# 10181, Durango, DGO.

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT00645177 - Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter